| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pharmacology, School of Medicine [J. S., S. M. S.] and Department of Chemistry, School of Arts and Sciences [Y. Q., A. D. H.], University of Pittsburgh, Pittsburgh, Pennsylvania 15261
Farnesylation of the oncoprotein Ras is required for its cancer-causing activity. We have designed farnesyltransferase inhibitor (FTI)-276, a tet-rapeptide mimetic of the carboxyl terminus of K-Ras4B, as a highly potent and selective inhibitor of Ras farnesylation in vitro and in vivo. FTI-276 blocked the growth in nude mice of a human lung carcinoma that expresses the two most prevalent genetic alterations in human cancers (K-Ras oncogenic mutation and deletion in the tumor suppressor gene p53). In contrast, FTI-276 did not inhibit tumor growth of a human lung carcinoma that harbors no Ras mutations. Furthermore, FTI-276 inhibited oncogenic signaling and tumor growth of NIH 3T3 cells transformed with the ras but not the raf oncogene. Inhibition of tumor growth in vivo was dose dependent and correlated with inhibition of Ras processing in tumors in vivo. The work described here identifies FTI-276 as a highly selective suppressor of Ras-dependent oncogenicity and suggests that a broad spectrum of human cancers with aberrant Ras function could benefit from farnesyltransferase inhibitor treatment.
1 This work was supported by NIH Grant CA-55823.
2 To whom requests for reprints should be addressed, at Department of Pharmacology-W1354, Biomedical Science Tower, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15261.
Received 7/12/95. Accepted 8/18/95.
This article has been cited by other articles:
|
|
 |
|
  Z. Liu, R. K. Meray, T. N. Grammatopoulos, R. A. Fredenburg, M. R. Cookson, Y. Liu, T. Logan, and P. T. Lansbury Jr. Membrane-associated farnesylated UCH-L1 promotes {alpha}-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease PNAS, March 24, 2009; 106(12): 4635 - 4640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. deCathelineau and G. M. Bokoch Inactivation of Rho GTPases by Statins Attenuates Anthrax Lethal Toxin Activity Infect. Immun., January 1, 2009; 77(1): 348 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Perl, C.-S. Chung, U. Perl, J. Lomas-Neira, M. de Paepe, W. G. Cioffi, and A. Ayala Fas-induced Pulmonary Apoptosis and Inflammation during Indirect Acute Lung Injury Am. J. Respir. Crit. Care Med., September 15, 2007; 176(6): 591 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Basso, P. Kirschmeier, and W. R. Bishop Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors J. Lipid Res., January 1, 2006; 47(1): 15 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tabernero, F. Rojo, I. Marimon, M. Voi, J. Albanell, M. Guix, F. Vazquez, J. Carulla, M. Cooper, J. Andreu, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors J. Clin. Oncol., April 10, 2005; 23(11): 2521 - 2533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. R. Khuri, B. S. Glisson, E. S. Kim, P. Statkevich, P. F. Thall, M. L. Meyers, R. S. Herbst, R. F. Munden, C. Tendler, Y. Zhu, et al. Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors Clin. Cancer Res., May 1, 2004; 10(9): 2968 - 2976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kurzrock, H. M. Kantarjian, J. E. Cortes, N. Singhania, D. A. Thomas, E. F. Wilson, J. J. Wright, E. J. Freireich, M. Talpaz, and S. M. Sebti Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting Blood, December 15, 2003; 102(13): 4527 - 4534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Delmas, D. End, P. Rochaix, G. Favre, C. Toulas, and E. Cohen-Jonathan The Farnesyltransferase Inhibitor R115777 Reduces Hypoxia and Matrix Metalloproteinase 2 Expression in Human Glioma Xenograft Clin. Cancer Res., December 1, 2003; 9(16): 6062 - 6068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Lancet and J. E. Karp Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy Blood, December 1, 2003; 102(12): 3880 - 3889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Fiordalisi, R. L. Johnson II, C. A. Weinbaum, K. Sakabe, Z. Chen, P. J. Casey, and A. D. Cox High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase Inhibitors J. Biol. Chem., October 24, 2003; 278(43): 41718 - 41727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mazzocca, S. Giusti, A. D. Hamilton, S. M. Sebti, P. Pantaleo, and V. Carloni Growth Inhibition by the Farnesyltransferase Inhibitor FTI-277 Involves Bcl-2 Expression and Defective Association with Raf-1 in Liver Cancer Cell Lines Mol. Pharmacol., January 1, 2003; 63(1): 159 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Walters, G. Pryce, D. J. R. Hankey, S. M. Sebti, A. D. Hamilton, D. Baker, J. Greenwood, and P. Adamson Inhibition of Rho GTPases with Protein Prenyltransferase Inhibitors Prevents Leukocyte Recruitment to the Central Nervous System and Attenuates Clinical Signs of Disease in an Animal Model of Multiple Sclerosis J. Immunol., April 15, 2002; 168(8): 4087 - 4094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Rose, F. Y. F. Lee, C. R. Fairchild, M. Lynch, T. Monticello, R. A. Kramer, and V. Manne Preclinical Antitumor Activity of BMS-214662, a Highly Apoptotic and Novel Farnesyltransferase Inhibitor Cancer Res., October 1, 2001; 61(20): 7507 - 7517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Morgan, O. Dolp, and C. W. M. Reuter Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling Blood, March 15, 2001; 97(6): 1823 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Cohen-Jonathan, S. M. Evans, C. J. Koch, R. J. Muschel, W. G. McKenna, J. Wu, and E. J. Bernhard The Farnesyltransferase Inhibitor L744,832 Reduces Hypoxia in Tumors Expressing Activated H-ras Cancer Res., March 1, 2001; 61(5): 2289 - 2293. [Abstract] [Full Text]
|
|
|
|
|
|
D. W. End, G. Smets, A. V. Todd, T. L. Applegate, C. J. Fuery, P. Angibaud, M. Venet, G. Sanz, H. Poignet, S. Skrzat, et al. Characterization of the Antitumor Effects of the Selective Farnesyl Protein Transferase Inhibitor R115777 in Vivo and in Vitro Cancer Res., January 1, 2001; 61(1): 131 - 137. [Abstract] [Full Text]
|
|
|
|
|
|
C. W. M. Reuter, M. A. Morgan, and L. Bergmann Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood, September 1, 2000; 96(5): 1655 - 1669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Glass, T.-J. Liu, and W.K. A. Yung Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336 Neuro-oncol, July 1, 2000; 2(3): 151 - 158. [Abstract] [PDF]
|
|
|
|
|
|
C. A. Omer, Z. Chen, R. E. Diehl, M. W. Conner, H. Y. Chen, M. E. Trumbauer, S. Gopal-Truter, G. Seeburger, H. Bhimnathwala, M. T. Abrams, et al. Mouse Mammary Tumor Virus-Ki-rasB Transgenic Mice Develop Mammary Carcinomas That Can Be Growth-inhibited by a Farnesyl:Protein Transferase Inhibitor Cancer Res., May 1, 2000; 60(10): 2680 - 2688. [Abstract] [Full Text]
|
|
|
|
|
|
J. Zujewski, I. D. Horak, C. J. Bol, R. Woestenborghs, C. Bowden, D. W. End, V. K. Piotrovsky, J. Chiao, R. T. Belly, A. Todd, et al. Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer J. Clin. Oncol., February 14, 2000; 18(4): 927 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Boota, B. Johnson, K.-L Lee, M. A. Blaskovich, S.-X. Liu, V. E. Kagan, A. Hamilton, B. Pitt, S. M. Sebti, and P. Davies Prenyltransferase inhibitors block superoxide production by pulmonary vascular smooth muscle Am J Physiol Lung Cell Mol Physiol, February 1, 2000; 278(2): L329 - L334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yang, J. Urano, and F. Tamanoi Protein Farnesylation Is Critical for Maintaining Normal Cell Morphology and Canavanine Resistance in Schizosaccharomyces pombe J. Biol. Chem., January 7, 2000; 275(1): 429 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Jiang, D. Coppola, N. C. Crespo, S. V. Nicosia, A. D. Hamilton, S. M. Sebti, and J. Q. Cheng The Phosphoinositide 3-OH Kinase/AKT2 Pathway as a Critical Target for Farnesyltransferase Inhibitor-Induced Apoptosis Mol. Cell. Biol., January 1, 2000; 20(1): 139 - 148. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. E. Lantry, Z. Zhang, R. Yao, K. A. Crist, Y. Wang, J. Ohkanda, A. D. Hamilton, S. M. Sebti, R. A. Lubet, and M. You Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone Carcinogenesis, January 1, 2000; 21(1): 113 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Nielsen, B. Shi, G. Hajian, B. Yaremko, P. Lipari, E. Ferrari, M. Gurnani, M. Malkowski, J. Chen, W. R. Bishop, et al. Combination Therapy with the Farnesyl Protein Transferase Inhibitor SCH66336 and SCH58500 (p53 Adenovirus) in Preclinical Cancer Models Cancer Res., December 1, 1999; 59(23): 5896 - 5901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Jansen, H. Schlagbauer-Wadl, H. Kahr, E. Heere-Ress, B. X. Mayer, H.-G. Eichler, H. Pehamberger, M. Gana-Weisz, E. Ben-David, Y. Kloog, et al. Novel Ras antagonist blocks human melanoma growth PNAS, November 23, 1999; 96(24): 14019 - 14024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Rowinsky, J. J. Windle, and D. D. Von Hoff Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development J. Clin. Oncol., November 1, 1999; 17(11): 3631 - 3652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Du and G. C. Prendergast Geranylgeranylated RhoB Mediates Suppression of Human Tumor Cell Growth by Farnesyltransferase Inhibitors Cancer Res., November 1, 1999; 59(21): 5492 - 5496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sun, M. A. Blaskovich, D. Knowles, Y. Qian, J. Ohkanda, R. D. Bailey, A. D. Hamilton, and S. M. Sebti Antitumor Efficacy of a Novel Class of Non-thiol-containing Peptidomimetic Inhibitors of Farnesyltransferase and Geranylgeranyltransferase I: Combination Therapy with the Cytotoxic Agents Cisplatin, Taxol, and Gemcitabine Cancer Res., October 1, 1999; 59(19): 4919 - 4926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Del Villar, J. Urano, L. Guo, and F. Tamanoi A Mutant Form of Human Protein Farnesyltransferase Exhibits Increased Resistance to Farnesyltransferase Inhibitors J. Biol. Chem., September 17, 1999; 274(38): 27010 - 27017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Du, A. Liu, and G. C. Prendergast Activation of the PI3'K-AKT Pathway Masks the Proapoptotic Effects of Farnesyltransferase Inhibitors Cancer Res., September 1, 1999; 59(17): 4208 - 4212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hernandez-Alcoceba, F. Fernandez, and J. C. Lacal In Vivo Antitumor Activity of Choline Kinase Inhibitors: A Novel Target for Anticancer Drug Discovery Cancer Res., July 1, 1999; 59(13): 3112 - 3118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Du, P. F. Lebowitz, and G. C. Prendergast Elevation of {{alpha}}2(I) Collagen, a Suppressor of Ras Transformation, Is Required for Stable Phenotypic Reversion by Farnesyltransferase Inhibitors Cancer Res., May 1, 1999; 59(9): 2059 - 2063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sun, Y. Qian, Z. Chen, J. Marfurt, A. D. Hamilton, and S. M. Sebti The Geranylgeranyltransferase I Inhibitor GGTI-298 Induces Hypophosphorylation of Retinoblastoma and Partner Switching of Cyclin-dependent Kinase Inhibitors. A POTENTIAL MECHANISM FOR GGTI-298 ANTITUMOR ACTIVITY J. Biol. Chem., March 12, 1999; 274(11): 6930 - 6934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Du, P. F. Lebowitz, and G. C. Prendergast Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB Mol. Cell. Biol., March 1, 1999; 19(3): 1831 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Law, P. Norgaard, L. Gnudi, B. B. Kahn, H. S. Poulson, and H. L. Moses Inhibition of DNA Synthesis by a Farnesyltransferase Inhibitor Involves Inhibition of the p70s6k Pathway J. Biol. Chem., February 19, 1999; 274(8): 4743 - 4748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Norgaard, B. Law, H. Joseph, D. L. Page, Y. Shyr, D. Mays, J. A. Pietenpol, N. E. Kohl, A. Oliff, R. J. Coffey Jr., et al. Treatment with Farnesyl-Protein Transferase Inhibitor Induces Regression of Mammary Tumors in Transforming Growth Factor (TGF) {{alpha}} and TGF{{alpha}}/neu Transgenic Mice by Inhibition of Mitogenic Activity and Induction of Apoptosis Clin. Cancer Res., January 1, 1999; 5(1): 35 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Suzuki, J. Urano, and F. Tamanoi Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells PNAS, December 22, 1998; 95(26): 15356 - 15361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Suzuki, K. Del Villar, and F. Tamanoi Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents PNAS, September 1, 1998; 95(18): 10499 - 10504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yonemoto, T. Satoh, H. Arakawa, I. Suzuki-Takahashi, Y. Monden, T. Kodera, K. Tanaka, T. Aoyama, Y. Iwasawa, T. Kamei, et al. J-104,871, a Novel Farnesyltransferase Inhibitor, Blocks Ras Farnesylation In Vivo in a Farnesyl Pyrophosphate-Competitive Manner Mol. Pharmacol., July 1, 1998; 54(1): 1 - 7. [Abstract] [Full Text]
|
|
|
|
|
|
W. W. Stark Jr., M. A. Blaskovich, B. A. Johnson, Y. Qian, A. Vasudevan, B. Pitt, A. D. Hamilton, S. M. Sebti, and P. Davies Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells Am J Physiol Lung Cell Mol Physiol, July 1, 1998; 275(1): L55 - L63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Barrington, M. A. Subler, E. Rands, C. A. Omer, P. J. Miller, J. E. Hundley, S. K. Koester, D. A. Troyer, D. J. Bearss, M. W. Conner, et al. A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis Mol. Cell. Biol., January 1, 1998; 18(1): 85 - 92. [Abstract] [Full Text]
|
|
|
|
|
|
A. Vogt, J. Sun, Y. Qian, A. D. Hamilton, and S. M. Sebti The Geranylgeranyltransferase-I Inhibitor GGTI-298 Arrests Human Tumor Cells in G0/G1 and Induces p21WAF1/CIP1/SDI1 in a p53-independent Manner J. Biol. Chem., October 24, 1997; 272(43): 27224 - 27229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Heasley, S. Thaler, M. Nicks, B. Price, K. Skorecki, and R. A. Nemenoff Induction of Cytosolic Phospholipase A2 by Oncogenic Ras in Human Non-small Cell Lung Cancer J. Biol. Chem., June 6, 1997; 272(23): 14501 - 14504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Finder, J. L. Litz, M. A. Blaskovich, T. F. McGuire, Y. Qian, A. D. Hamilton, P. Davies, and S. M. Sebti Inhibition of Protein Geranylgeranylation Causes a Superinduction of Nitric-oxide Synthase-2 by Interleukin-1beta in Vascular Smooth Muscle Cells J. Biol. Chem., May 23, 1997; 272(21): 13484 - 13488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. McGuire, Y. Qian, A. Vogt, A. D. Hamilton, and S. M. Sebti Platelet-derived Growth Factor Receptor Tyrosine Phosphorylation Requires Protein Geranylgeranylation but not Farnesylation J. Biol. Chem., November 1, 1996; 271(44): 27402 - 27407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Lerner, Y. Qian, A. D. Hamilton, and S.īd M. Sebti Disruption of Oncogenic K-Ras4B Processing and Signaling by a Potent Geranylgeranyltransferase I Inhibitor J. Biol. Chem., November 10, 1995; 270(45): 26770 - 26773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Lerner, Y. Qian, M. A. Blaskovich, R. D. Fossum, A. Vogt, J. Sun, A. D. Cox, C. J. Der, A. D. Hamilton, and S.īd M. Sebti Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes J. Biol. Chem., November 10, 1995; 270(45): 26802 - 26806. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
